Drug Trial Radar · NCT07181161
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
283
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Jan 18, 2029
Study completion Jan 18, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Conditions
- Metastatic Prostate Cancer
Interventions
AZD0516Drug
AZD0516 will be administered via intravenous infusion.
AZD9574Drug
AZD9574 will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs)Time frame: From Day 1 up to approximately 3 years
- Module 1 and 2: Part A: Number of participants with Dose Limiting Toxicities (DLTs)Time frame: From Day 1 up to end of DLT period (approximately 21 days)
- Module 1: Parts B and C and Module 2: Part B: Percentage of participants with Prostate-Specific Antigen (PSA) 50 response rateTime frame: Up to approximately 2 years
Locations
52 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Fayetteville, Arkansas · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Towson, Maryland · Suspended
Research Site
Boston, Massachusetts · Recruiting
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Buffalo, New York · Suspended
Research Site
New York, New York · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Myrtle Beach, South Carolina · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Barretos, Brazil · Not yet recruiting
Research Site
Porto Alegre, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Chengdu, China · Not yet recruiting
Research Site
Wuhan, China · Not yet recruiting
Research Site
Lyon, France · Withdrawn
Research Site
Montpellier, France · Withdrawn
Research Site
Saint-Herblain, France · Withdrawn
Research Site
Suresnes, France · Withdrawn
Research Site
Villejuif, France · Withdrawn
Research Site
Milan, Italy · Not yet recruiting
Research Site
Milan, Italy · Not yet recruiting
Research Site
Milan, Italy · Not yet recruiting
Research Site
Naples, Italy · Not yet recruiting
Research Site
Roma, Italy · Not yet recruiting
Research Site
Rozzano, Italy · Not yet recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Kōtoku, Japan · Recruiting
Research Site
Koszalin, Poland · Not yet recruiting
Research Site
Piotrkow Trybunalski, Poland · Not yet recruiting
Research Site
Przemyśl, Poland · Not yet recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Barcelona, Spain · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.